Back to jobs
New

Senior Director, Medical Affairs Strategy, Oncology

Boston, MA

Company Overview

Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.

Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.

This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.

Tango’s labs offices are located at 201 Brookline Avenue, in the vibrant Fenway area of Boston, Massachusetts.

 

Summary

Tango Therapeutics is seeking an experienced Senior Director, Medical Affairs Strategy, Oncology. Reporting to the Executive Director of Medical Affairs, this individual will shape and execute the medical strategy supporting product life-cycle management including registration and launch activities, evidence generation, external expert engagement planning, and patient advocacy partnerships.

The role will serve as a key strategic partner to Clinical Development, Clinical Operations, Medical Information, Scientific Communications, HEOR/RWE, Biomarkers/Diagnostics, Commercial, Market Access, Regulatory, Safety, Legal, Compliance, and Field Medical to ensure the evidence generated addresses the needs of healthcare professionals, patients, patient advocacy groups, and payers through late-stage development and launch. 

 

Your Role:

Medical Affairs Strategy

  • Lead development and execution of integrated medical affairs plans across oncology programs
  • Lead medical launch-readiness planning, including pre-launch engagement objectives, resource planning, medical education planning, and integration with registrational and post-approval evidence plans
  • Translate clinical development objectives into evidence generation and stakeholder engagement strategies
  • Develop and maintain routine medical plans aligned with corporate objectives

Scientific Leadership

  • Provide scientific leadership, directing medical affairs team members supporting late-stage development, and partnering with Field Medical to translate medical strategy into engagement objectives, resource plans, tactics, and listening priorities that MSLs execute through scientific exchange
  • Ensure scientific consistency across programs and therapeutic areas
  • Define engagement planning objectives, resource plans, tactics, and insight-listening priorities for advisory boards, congress strategy, and external expert engagement, with scientific exchange executed by Field Medical MSLs

Evidence Generation

  • Lead the Medical Affairs evidence-generation strategy through late-stage development and launch
  • Prioritize evidence gaps and develop plans to address scientific and clinical questions arising from late-stage and registrational studies
  • Oversee real-world evidence, outcomes research, and post-approval evidence planning

HEOR and RWE

  • Provide medical input to HEOR and RWE strategies supporting value demonstration, in partnership with the HEOR partners
  • Collaborate with Market Access and Commercial teams to generate evidence relevant to payers and healthcare systems
  • Guide protocol development and data interpretation

IIS and Collaborative Research

  • Develop governance and strategy for investigator-sponsored studies
  • Evaluate research proposals and prioritize the IIS portfolio against late-stage evidence needs
  • Manage external scientific collaborations and academic partnerships
  • Ensure alignment between IIS investments and organizational objectives

Patient Advocacy

  • Build and maintain relationships with patient advocacy organizations, incorporate patient perspectives into medical strategy and evidence planning, and ensure all engagement complies with applicable legal and compliance requirements

Cross-Functional Partnership

  • Partner with Clinical Development to support lifecycle evidence planning
  • Collaborate with Biomarker and Diagnostic teams on precision medicine strategies
  • Work closely with Medical Information, Scientific Communications, and Field Medical teams to ensure coordinated execution, including feeding field insights back into engagement planning

Medical Governance

  • Support medical review and governance activities
  • Ensure compliance with all legal, regulatory, and ethical requirements
  • Contribute to SOP development and medical affairs operating procedures

 

What You Bring:

Required 

  • MD, PharmD, or PhD in a life sciences discipline; MD preferred
  • 12+ years pharmaceutical/biotech experience
  • 7+ years within oncology Medical Affairs
  • 4+ years of experience in Medical Affairs strategic roles
  • Demonstrated success leading cross-functional initiatives

Preferred

  • Experience supporting registration-enabling or launch-stage oncology products
  • Strong background in HEOR, RWE, or post-marketing evidence generation
  • Experience partnering and leading in cross-matrix teams, and engaging patient advocacy organizations
  • Precision oncology and biomarker experience
  • Small biotechnology company experience

 

We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.

Salary range

$296,000 - $444,000 USD

Create a Job Alert

Interested in building your career at Tango Therapeutics? Get future opportunities sent straight to your email.

Apply for this job

*

indicates a required field

Phone
Resume/CV*

Accepted file types: pdf, doc, docx, txt, rtf

Cover Letter

Accepted file types: pdf, doc, docx, txt, rtf


Education

Select...
Select...

Select...

Please feel welcome to provide your pronouns

Voluntary Self-Identification

For government reporting purposes, we ask candidates to respond to the below self-identification survey. Completion of the form is entirely voluntary. Whatever your decision, it will not be considered in the hiring process or thereafter. Any information that you do provide will be recorded and maintained in a confidential file.

As set forth in Tango Therapeutics’s Equal Employment Opportunity policy, we do not discriminate on the basis of any protected group status under any applicable law.

Select...
Select...
Race & Ethnicity Definitions

If you believe you belong to any of the categories of protected veterans listed below, please indicate by making the appropriate selection. As a government contractor subject to the Vietnam Era Veterans Readjustment Assistance Act (VEVRAA), we request this information in order to measure the effectiveness of the outreach and positive recruitment efforts we undertake pursuant to VEVRAA. Classification of protected categories is as follows:

A "disabled veteran" is one of the following: a veteran of the U.S. military, ground, naval or air service who is entitled to compensation (or who but for the receipt of military retired pay would be entitled to compensation) under laws administered by the Secretary of Veterans Affairs; or a person who was discharged or released from active duty because of a service-connected disability.

A "recently separated veteran" means any veteran during the three-year period beginning on the date of such veteran's discharge or release from active duty in the U.S. military, ground, naval, or air service.

An "active duty wartime or campaign badge veteran" means a veteran who served on active duty in the U.S. military, ground, naval or air service during a war, or in a campaign or expedition for which a campaign badge has been authorized under the laws administered by the Department of Defense.

An "Armed forces service medal veteran" means a veteran who, while serving on active duty in the U.S. military, ground, naval or air service, participated in a United States military operation for which an Armed Forces service medal was awarded pursuant to Executive Order 12985.

Select...